There are 16 resources available
Beyond the science: Bottlenecks in implementation of EGFR molecular testing in NSCLC
Presenter: A.M. C. Dingemans, NL
Session: Session 3 – Detecting EGFR E20I mutations: Diagnostic issues and challenges
Resources:
Slides
Webcast
Optimal management of toxicity in patients with advanced NSCLC treated with EGFR E20I inhibitors: Are they all similar?
Presenter: R. A. Soo, SG
Session: Session 4 – Clinical challenges
Resources:
Slides
Webcast
Are all EGFR E20I mutations similar and are all inhibitors of comparable efficacy?
Presenter: S.H. Lee, KR
Session: Session 4 – Clinical challenges
Resources:
Slides
Webcast
Emerging mechanisms of resistance to EGFR E20I inhibitors and research on combinations of EGFR E20I inhibitors with cytotoxic chemotherapy or novel targeted therapeutics
Presenter: F. Cappuzzo, IT
Session: Session 4 – Clinical challenges
Resources:
Slides
Webcast
Optimal positioning and sequencing of EGFR E20I inhibitors: Research perspectives for (neo-)adjuvant use and 1st line of advanced disease
Presenter: P. A. Jänne, US
Session: Session 5 – Optimising use of EGFR E20I mutations
Resources:
Slides
Webcast
Presentation of clinical cases of advanced NSCLC patients treated with immunotherapy and subsequent diagnosis of EGFR E20I mutations: Considerations of efficacy and safety
Presenter: S. M. Lim, KR
Session: Session 5 – Optimising use of EGFR E20I mutations
Resources:
Slides
Webcast